Trial Profile
Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P BCMA-101 in Subjects With Relapsed / Refractory Multiple Myeloma (MM) Followed by a Phase 2 Assessment of Response and Safety (PRIME)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs P-BCMA-101 (Primary) ; Cyclophosphamide; Fludarabine; Rimiducid
- Indications Multiple myeloma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms PRIME
- Sponsors Poseida Therapeutics
- 17 May 2022 Status changed from active, no longer recruiting to discontinued. Phase I portion of the study was completed. The phase II portion of the study was terminated early to focus on an Allogeneic BCMA CAR-T program.
- 10 Mar 2022 According to a Poseida Therapeutics media release, full results of the ASH update from this trial can be found on the Companys website.
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition